Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia
Status:
Not yet recruiting
Trial end date:
2024-02-29
Target enrollment:
Participant gender:
Summary
This is a Phase IIa,multicentre proof of concept study consisting of 2 study periods to study
Treatment with NST-1024 as an adjunct to diet to reduce triglyceride (TG) levels in subjects
with TG levels of ≥500 mg/dL and ≤2000 mg/dL; determined by percentage change in TG from
baseline after 28 days of treatment.
The two periods consist of:
1. A 3-week screening period that includes a TG qualifying period, and
2. A 28-days, double-blind, randomized, parallel group, placebo-controlled treatment
period.
Subjects will return to the study site for a follow-up visit 2 weeks after the last dose.
Approximately 50 subjects will be randomized at approximately 15-20 centres in USA.